Eosinophil granule major basic protein (MBP), a potent toxin for helminths and mammalian cells in vitro, is a single polypeptide chain rich in arginine. MBP has been localized on damaged helminths and tissues in hypersensitivity diseases including bronchial asthma. The MBP cDNA indicates that MBP is translated as a slightly acidic preproprotein with an acidic propart. To test the hypothesis that the acidic pro-part of proMBP inhibits the toxicity of mature MBP, acidic polyamino acids (aa) were used as antagonists of MBP toxicity to K562 cells and guinea pig tracheal epithelium and used as antagonists of MBP airway hyperresponsiveness in primates. The acidic poly aa inhibited MBP toxicity and MBP airway hyperresponsiveness. The acidic poly aa inhibited MBP toxicity in a charge-dependent manner similar to that proposed for proMBP, suggesting that the acidic pro-part of proMBP functions to mask mature MBP toxicity. This inhibition was not limited to MBP, but also applied to polyarginine and eosinophil cationic protein. These acidic poly aa may be useful to inhibit the actions ofa number of cationic toxins released by the eosinophil in numerous hypersensitivity diseases. (J. Clin. Invest. 1991. 88:798-805.)
Introduction
The eosinophilic leukocyte contains a number of cationic toxins. Major basic protein (MBP),' the predominant protein in eosinophils, comprises the crystalloid core of the eosinophil granule (1) and in humans is a 117-amino acid (aa) residue 1. Abbreviations used in this paper: aa, amino acid; DCS, defined calf serum; e, electronic charge; ECP, eosinophil cationic protein; MBP, major basic protein; metacholine P100, the dose ofinhaled metacholine required to cause a 100% increase in Rrs; Rrs, respiratory system resistance.
single polypeptide rich in arginine (2) . MBP likely damages cell membranes (3, 4) and is a potent toxin for helminths and mammalian cells in vitro (1) . It has been localized on damaged helminths and tissues in hypersensitivity diseases including bronchial asthma. MBP causes extensive damage to guinea pig and human respiratory epithelium; this damage mimics the pathology of asthma, suggesting that eosinophils are a prime effector cell for tissue damage in bronchial asthma (1) . MBP instillation into the trachea of primates results in a significant increase in airway responsiveness, indicating a direct role for MBP in the pathogenesis of airway hyperresponsiveness (5) .
The MBP cDNA from the promyelocytic cell line HL-60, which produces MBP, indicates that MBP is translated as a slightly acidic preproprotein with an acidic pro-part (6) . Human MBP (2) contains a high portion of aa with hydrophobic side chains, 17 arginines, only one carboxylic acid-containing residue, and has a calculated electronic charge (e) (calculated by Titrate program, DNAstar, Inc., Madison, WI) of 16.3 (7) . The 90-aa residue acidic pro-part of proMBP contains 20 glutamic acids, 6 aspartic acids, 7 strongly basic aa, and has a calculated e of -19.0. The combination ofthe acidic and basic peptides in proMBP has an almost neutral e of -2.58.
Previously, we suggested that the acidic pro-part of proMBP masks the toxic effects of mature MBP and protects the eosinophil from damage while the protein is processed through the endoplasmic reticulum to its sequestered site in the eosinophil granule as toxic MBP (6) .
To test the hypothesis that the acidic pro-part of proMBP inhibits mature MBP toxicity, acidic poly aa were used as substitutes for the acidic pro-part of proMBP which has not yet been isolated in its native state or obtained in a recombinant form. Here, we report that acidic poly aa inhibited MBP toxicity to K562 cells and guinea pig tracheal epithelium and inhibited MBP airway hyperresponsiveness in primates. Acidic poly aa inhibited MBP toxicity in a charge-dependent manner similar to that proposed for proMBP, providing evidence that the acidic pro-part of proMBP functions to neutralize toxic MBP and suggesting a possible therapy for bronchial asthma. 
Purification ofMBP and eosinophil cationic protein
Eosinophils from patients with hypereosinophilic syndrome were obtained by cytapheresis as previously described (8, 9) . The procedures for purification of human eosinophil granules, MBP, and eosinophil cationic protein (ECP) have been described in detail elsewhere (10, 11 (12) .
Guinea pig tracheal ring assay
Tracheal rings were prepared from Hartley guinea pigs (Mayo Institute Hills Farm, Rochester, MN) as previously described (13) . Briefly, immediately after CO2 euthanasia tracheas were removed and placed in RPMI 1640. Adherent connective tissue was trimmed and each trachea was cut transversely into a series of 1-mm thick rings using a previously described slicing device (14) . After overnight equilibration, each ring was carefully examined to determine that the mucosa was intact and actively beating cilia were present. Rings with damaged mucosa were not used for experimentation. For testing, rings were transferred to 96-well microtiter plates containing 100 MI RPMI 1640/well. 50 Ml of acidic poly aa at a final concentration of 1.4 X 10-5 M or RPMI 1640 alone were added followed within S min by 50 Ml of MBP at a final concentration of 1.4 X 10-M or controls (column buffer or RPMI 1640). MBP was not used at 5 x 10-6 M as in K562 assays, because this concentration did not cause complete cessation of ciliary motion of tracheal ring epithelial cells Acidic Amino Acids Inhibit Major Basic Protein Toxicity 799 over the assay period. An observer, unaware ofthe substance or combination being tested, examined the ring cultures at 24 h and 48 h using an inverted microscope. After final observations, specimens were fixed in 10% buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin.
Criteria for damage to tracheal epithelium Our criteria for damage to the ciliated epithelium of the guinea pig tracheal rings were similar to those used previously (13) . The term ciliostasis is used to describe the complete cessation of ciliary motion throughout the entire tracheal ring; "normal" tracheal rings had active, intact ciliary epithelium. At the time intervals when damage was assessed, ciliostasis was almost always accompanied by partial or complete exfoliation or "stripping" of the ciliated epithelial cells from the basement membrane of the mucosa with precipitates of MBP on or around the cells.
Airway hyperresponsiveness and inhibition of hyperresponsiveness assays
Animals. The animals used in this study were wild-caught adult male cynomolgus monkeys (Macacafascicularis) weighing 3.5-7.5 kg. Each animal was housed individually in a specially designed open mesh cage and provided with food twice daily and water ad lib. Animals were fasted for -18 h before study.
Study protocol. Each animal was anesthetized with an intramuscular injection of ketamine (4 mg/kg) and xylazine (1 mg/kg), intubated with a cuffed endotracheal tube, and seated in an upright position in a specially designed support chair. Ketamine (4 mg/kg, i.m.) was used to supplement anesthesia when needed. Baseline respiratory system resistance (Rrs) was monitored for 15 min followed by methacholine doseresponse determinations (15, 16) . Bronchoconstrictor response to inhaled methacholine was used to determine airway responsiveness. After completion of the methacholine dose-response, each animal received an aerosol treatment of either vehicle or polyglutamic acid (P-4886, 61,200 mol wt; Sigma; this polyglutamic acid is a different lot and molecular weight from that ofthe P-4886 listed in Table I ). Rrs was monitored for an additional 10 min after which each animal received an intratracheal injection ofnative MBP. Rrs was then monitored for 1 h postinstillation after which the animals were allowed to recover from anesthesia. At 2 h postinstillation each animal was anesthetized (ketamine/xylazine), intubated, and methacholine dose-response determinations were performed. The study was designed so that the polyglutamic acid treatment experiments were bracketed by control (vehicle) treatment studies to ensure no change in MBP-induced effects over time.
Intratracheal MBP instillation. Native MBP was diluted in column buffer to a concentration of200 ,g/ml immediately before instillation. A total of 5 ml (1 mg MBP) was slowly infused directly into the trachea through the endotracheal tube via a 20-cm long piece of polyethylene 240 tubing attached to a 5-ml syringe. As control fluids, PBS and column buffer were tested and produced no effect on Rrs or methacholine sensitivity.
Rrs measurements. Respiratory system impedance was measured by discrete frequency sinusoidal forced oscillations superimposed on tidal breathing as previously described (15 
Inhibition ofblood clotting
To determine whether acidic poly aa inhibit blood clotting, stock concentrations ofheparin, poly-L-glutamic acid 13,600 mol wt, poly-L-glutamic acid 77,800 mol wt, and/or MBP each at 1 X 10-' M were added to 500 ul whole blood from a normal human volunteer to final concentrations of 10-4 M to 10-6 M in 10 X 75-mm glass tubes and mixed. PBS and column buffer were used as controls. The tubes were checked at 1-min intervals and clotting time for each sample was recorded. After 30 min, samples were checked every 30 min to a maximum of 15 h.
Results
Inhibition of MBP toxicity to K562 cells by acidic poly aa.
Various polyglutamic and polyaspartic aa were added to K562 cells followed by addition of MBP and cell viability was determined after 4 h ( Table II) . The poly aa ranged from 6,800 to 77,800 in mol wt (Table I) and were tested at concentrations from 1 x l0-`M to 5 x 10-6 M for their ability to inhibit MBP toxicity at 5 X 10-6 M. All of the acidic poly aa inhibited MBP toxicity at equimolar MBP concentrations (Table II) . This inhibition was related to the acidic or anionic nature of the polymers because poly-L-asparagine at 5 X 10-6 M did not inhibit MBP toxicity. Also, some degree of polymerization was necessary for this effect because acidic amino acid monomers did not inhibit MBP toxicity. The acidic amino acids themselves were not toxic to the K562 cells at the concentrations tested.
As the concentration of the acidic poly aa was lowered below that of MBP, inhibition of MBP toxicity to the K562 cells was reduced (Table II) . This reduction was not due to the type of acidic poly aa (glutamic versus aspartic or D versus L isomers) but was dependent upon the molecular weight and thus the degree of polymerization of the acidic aa. Because the degree of polymerization directly affects the total e ofthe acidic polymers, a comparison between the acidic poly aa concentrations necessary to balance the e of MBP at 5 X 10-6 M and the reduction in acidic poly aa inhibition of MBP toxicity to K562 cells was made (Tables I and II) . At acidic polymer concentrations greater than or equal to those necessary to balance e of MBP only poly-L-aspartic acid (1 1,500 mol wt) and poly-L-glutamic acid (13,600 mol wt), both at 1 x 10-6 M, were significantly different from controls; however, at acidic polymer concentrations less than those necessary to balance e of MBP, all polymers exhibited a drastic reduction in their ability to inhibit MBP toxicity. These data suggest that the e of an acidic poly aa is a critical determinant of its ability to inhibit MBP toxicity.
To better define the point at which acidic poly aa begin to effectively inhibit MBP toxicity, several of the acidic polymers were tested at 2.0, 1.0, and 0.5 times the concentration necessary to balance e of MBP at 5 x 10-6 M (Fig. 1 ). All four polymers tested inhibited MBP toxicity to K562 cells at a concentration of 2.0 times e and were not significantly different from the medium control, although poly-DL-aspartic acid, the smallest polymer used in the study, was the least effective. At a concentration of 1.0 times e the polyaspartic acids were significantly different from the controls while the polyglutamic acids were not; mean percent viability was lowest for poly-DL-aspartic acid (23.9±4.2) and highest for poly-L-glutamic acid 77,800 mol wt (89.1±2.3). All ofthe polymers were significantly different from the medium control at a concentration of 0.5 times e and afforded little protection against MBP. Thus, acidic poly aa begin to effectively protect K562 cells against MBP toxicity at concentrations between 1.0 and 2.0 times e. In the first set ofexperiments, the acidic poly aa were added to the K562 cells before MBP. The ability ofthe acidic poly aa to inhibit MBP toxicity after MBP had already been added to the cells was tested and the data are shown in Fig. 2 . Acidic poly aa concentrations which were effective in inhibiting MBP toxicity previously were not as effective in inhibiting MBP toxicity when MBP was added to the cells before the aa polymers. There is some protection when the acidic poly aa are added within 15 (Table I ) for a particular acidic poly aa. 1 l P < 0.05 for values tested against appropriate acidic poly aa controls using Student's t test; poly-L-arginine hydrochloride or ECP added within 5 min after addition of acidic poly aa.
15 min after MBP was not significantly different from its control. Increasing acidic poly aa concentrations 10-fold to 5 x 10-5 M (data not shown) at all addition times had no significant effect. Apparently, the acidic poly aa have little effect on K562 viability unless they are added before or immediately after addition of 5 X 10-6 M MBP. Inhibition ofpoly-L-arginine and ECP toxicity to K562 cells by acidic poly aa. To determine ifthis toxic inhibition by acidic poly aa is limited only to MBP or may apply to other cationic toxins, acidic poly aa were tested for their ability to inhibit poly-L-arginine and ECP toxicity to K562 cells. Both poly-L-arginine and ECP toxicity were inhibited by acidic poly aa (Table  III) . Generally, there were no significant differences between test concentrations and controls when acidic poly aa test concentrations were at least equal to the concentration needed for a balanced e for poly-L-arginine or ECP except for poly-L-glutamic acid 13,600 mol wt tested against ECP. Below acidic poly aa concentrations necessary for a balanced e, inhibition oftoxicity was greatly reduced for all acidic poly aa tested. Because these acidic poly aa inhibit poly-L-arginine and ECP toxicity, this mechanism is not specific to MBP and may apply to numerous cationic toxins.
Inhibition ofMBP toxicity to tracheal ring epithelium by acidic poly aa. Acidic poly aa were used as antagonists of MBP toxicity to guinea pig tracheal epithelium as a model for their role as an inhibitor of MBP toxicity in bronchial asthma. Polyglutamic acids inhibited MBP toxicity to the tracheal epithelium (Fig. 3) . Tracheal rings incubated with MBP alone exhibited gross morphologic damage at 24 h. The damage included ciliostasis and exfoliation ofmucosal cells. Precipitates ofMBP were apparent on and around the cells. After 48 h ofincubation only the MBP alone-treated tracheal rings showed damage (Fig. 3, A and B) . The tracheal rings treated with acidic polyglutamic acids or a combination of polyglutamic acids and MBP appeared normal with active cilia (Fig. 3, Cand D) . Some ofthe cilia of the rings treated with a combination of polyglutamic acids and MBP appeared to have a small amount ofprecipitate on them which may be polyglutamic acid and/or MBP (Fig. 3  D) . There was no detectable damage to the cilia associated with this precipitate.
Inhibition ofMBP-induced effects on the airway bypolyglutamic acid. MBP instillation resulted in an immediate increase in Rrs that peaked between 5 and 10 min postinstillation and resolved by 1 h (Fig. 4) . Pretreatment with polyglutamic acid significantly inhibited the MBP-induced increase in Rrs. Polyglutamic acid treatment by itself did not alter Rrs (data not shown).
The effects of MBP instillation on airway responsiveness to inhaled methacholine during control and polyglutamic acid treatment studies are shown in Fig. 5 . MBP administration alone resulted in a dramatic increase in airway responsiveness as indicated by a decrease in calculated methacholine PC,10 values. Polyglutamic acid pretreatment significantly inhibited the MBP-induced increase in airway responsiveness in each animal studied.
Effect ofacidic poly aa on blood clotting. Although heparin is an effective antagonist of MBP toxicity (1, 17) , its possible clinical use in bronchial asthma could be limited by its ability to inhibit blood clotting. To determine ifacidic poly aa inhibit blood clotting, whole blood was incubated with heparin, polyglutamic acids, and/or MBP, and the clotting time was observed. These data are shown in Fig. 6 . At a concentration of 1 X 10-5 M, twice the highest acidic poly aa concentration used in the K562 assays and comparable to that used in the tracheal ring assays, there was no significant difference between polyglutamic acids alone or polyglutamic acids + MBP when compared to controls in their ability to inhibit clotting. However, poly-L-glutamic acid 77,800 mol wt was significantly different from controls at 1 X 10-0 M. Heparin was significantly different from controls at all test concentrations and increased clotting time at least to 45 times that of poly-L-glutamic acid 77,800 molwtat l x 10-4M.
Discussion
The mechanism by which MBP kills cells is unknown. It has been suggested that the cationic charge of MBP may attract it to the anionic charged cell surface of targets, whereupon the apolar residues insert into and perturb the lipid milieu (2) . their permeability without concurrent formation oftransmembrane channels (3) .
In this study MBP toxicity to K562 cells and guinea pig tracheal epithelium was inhibited by acidic poly aa. This inhibition was directly related to the ability of negatively charged acidic poly aa to balance and thus neutralize the positively charged MBP. The ratio of the absolute values of the predicted e for the acidic pro-part of proMBP to the predicted e of cationic MBP is 1.2. Inhibition of MBP toxicity by acidic poly aa at concentrations above that necessary to balance charge (ratio of 1.0) but not significantly at concentrations below that necessary to balance charge (Table II; Fig. 1 ) suggests that the acidic pro-portion ofproMBP functions to mask MBP toxicity. Thus, it is likely that proMBP is a nontoxic molecule that protects the eosinophil from damage while the protein is processed through the endoplasmic reticulum to its sequestered site in the eosinophil granule as toxic MBP.
These data also show that the acidic poly aa must be added before or immediately after addition of 5 x 10-6 M MBP to inhibit its toxicity (Fig. 2) . Presumably, when MBP is added before the acidic polymers and allowed to incubate with the target for a short period of time, MBP will bind to the target membranes and will not be effectively inhibited by the acidic polymers after that time; addition ofacidic poly aa before MBP may allow them to bind to MBP preventing it from binding to the target membranes.
This has implications in the processing of proMBP. The presumed enzyme that cleaves proMBP is unknown. It is unlikely that this enzyme cleaves proMBP only at one point into pro-part and toxic MBP for several reasons. First, if proMBP were cleaved at only one point, it appears that at neutral or nearly neutral pH, the intact pro-part would still continue to be associated with mature MBP as are the acidic poly aa in this study and MBP would still be nontoxic while bound to the pro-part. Second, repeated attempts by Ponz et al. to identify a small acidic protein with the characteristics expected of the pro-part of BTAH, a cationic toxin similar to MBP, using gel filtration, preparative electrophoresis at alkaline pH, and HPLC were unsuccessful (18) . Third, the acidic pro-part of promellitin, a cationic toxin from bee venom that damages cell membranes, is cleaved every second residue by a dipeptidyl peptidase (19) . These data are in keeping with the hypothesis that the acidic pro-part of proMBP is cleaved in a stepwise fashion that results in toxic MBP and a number of smaller peptides which do not bind sufficiently to MBP, if at all, to inhibit its toxicity.
Polyarginine and ECP are potent toxins and although they may kill targets differently from MBP (3, 20) , polyarginine and ECP share with MBP the property of a highly cationic nature. Acidic poly aa inhibition of polyarginine and ECP toxicity to K562 cells (Table III) and ECP to the acidic poly aa, precluding the binding of these toxins to target cells. Because this inhibition is not restricted to MBP but also applies to ECP and polyarginine, treatment of target cells with acidic poly aa may perturb the toxic activities of numerous cationic toxins including those from eosinophils.
The ability of acidic poly aa (which were nontoxic and did not inhibit coagulation [ Fig. 6 ]) to inhibit MBP toxicity to tracheal ring epithelium (Fig. 3) and inhibit MBP airway hyperresponsiveness (Figs. 4 and 5) suggests a possible role for the acidic poly aa as therapy for many of the hypersensitivity diseases associated with eosinophil degranulation, especially bronchial asthma. Presently, it is not known whether these acidic poly aa would inhibit MBP and other cationic eosinophil degranulation products in vivo. Heparin, which has been shown to inhibit MBP toxicity (1, 17) , does inhibit whole eosinophil toxicity to Trypanosoma cruzi trypomastigotes (21) . Studies are underway to test the effectiveness of acidic poly aa to inhibit airway hyperresponsiveness associated with antigen induced asthma in the primate model. 
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